Evidence map›Paper›PMID 37731860›Full record

ArticleLaryngoscope investigative otolaryngology2023

Anticancer effects of thymoquinone in head and neck squamous cell carcinoma: A scoping review.

Kera Kwan, Albert Y Han, Laith Mukdad, Frida Barragan, Omar Selim, Yazeed Alhiyari, Maie St John

Abstract readScoping Review
PubMed Full text at PMC Publisher
In one paragraph

Article in Laryngoscope investigative otolaryngology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kera KwanUCLA Department of Surgery University of California Los Angeles California Los Angeles USA.ORCID https://orcid.org/0000-0002-3651-8915
Albert Y HanDepartment of Head and Neck Surgery University of Texas MD Anderson Cancer Center Houston Texas USA.
Laith MukdadUCLA Head and Neck Cancer Surgery University of California Los Angeles California Los Angeles USA.ORCID https://orcid.org/0000-0003-1842-7857
Frida BarraganUCLA Head and Neck Cancer Surgery University of California Los Angeles California Los Angeles USA.
Omar SelimUCLA Head and Neck Cancer Surgery University of California Los Angeles California Los Angeles USA.
Yazeed AlhiyariUCLA Head and Neck Cancer Surgery University of California Los Angeles California Los Angeles USA.
Maie St JohnUCLA Head and Neck Cancer Surgery University of California Los Angeles California Los Angeles USA.ORCID https://orcid.org/0000-0001-7068-9534

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Thymoquinone (TQ), the active constituent of Data Sources: Three databases (PubMed, Embase, and Google Scholar) were queried for the key words "thymoquinone squamous cell carcinoma." Review Methods: Publications that were not original research and publications that did not have full-text available for review were excluded. Results: Sixteen research articles met the inclusion criteria. Our review demonstrates that TQ-induced cytotoxicity is associated with increased expression and activity of the tumor suppressor p53, proapoptotic proteins Bax and caspases, as well as decreased expression and activity of antiapoptotic proteins Bcl-2 and Mdm2. Additionally, TQ modulates cell-survival pathways such as the PI3k/Akt pathway. TQ synergizes with therapeutics including cisplatin and radiation. Early TQ administration may prevent carcinogenesis via upregulation of antioxidant enzymes, and TQ administration in the presence of cancer can result in disease mitigation via induction of oxidative stress. Conclusion: TQ acts as an upregulator of proapoptotic pathways and downregulator of antiapoptotic pathways, modulates the oxidative stress balance in tumor development, and works synergistically alongside other chemotherapeutics to increase cytotoxicity. TQ has the potential to prevent carcinogenesis in patients who are at high-risk for SCC and adjuvant treatment for SCC patients undergoing conventional treatments. Future studies should aim to identify specific populations in which TQ's effects would be the most beneficial. Level of Evidence: Not available.

Indexed as

cutaneous < head and neckmolecular biologyscoping reviewskin cancer < head and neck

Identifiers

PMID37731860
PMCPMC10508265

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.